Neurologists who were asked about new treatments for amyotrophic lateral sclerosis (ALS) say they value efficacy and quality-of-life improvements over safety for drugs in development.
The typically rapid progression of the terminal disease is the chief factor in the safety sentiment, said Alissa Algarin, senior insights analyst at Spherix. As one neurologist told the surveyors: “In a condition like this, I’m more towards efficacy because if you’re dead it doesn’t matter how safe the drug was.”
Efficacy in delaying disease progression was picked as the top attribute by 52% of neurologists surveyed, followed by quality-of-life improvements (18%). Long-term safety concerns were noted as a top attribute by just 9%, according to data from a November survey from Spherix Global Insights.
Almost all of the neurologists surveyed (88%) agreed the most pressing unmet need in ALS is the development of true disease-modifying therapies. When asked what those future therapies might look…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks